Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron for overactive bladder after inadequate response to antimuscarinics or mirabegron
jRCT1071230070Recruiting
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vibegron in overactive bladder (OAB). Primary endpoint: Change from baseline in total OAB Symptom Score (OABSS). Started Sep 2023; status: recruiting.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on jRCT1071230070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1071230070.